FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE
FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE · ONE OF JUST 8 NATIONWIDE
RSV symptoms in adults typically begin as a common cold — nasal congestion, sore throat, mild cough, and low-grade fever — and in most healthy adults resolve within 7 to 10 days. However, in adults over 60, those with asthma or COPD, and the immunocompromised, RSV can progress to bronchiolitis or pneumonia and is now recognized as a leading cause of respiratory hospitalization in older adults. RSV is contagious for 3 to 8 days on average, though immunocompromised patients can shed virus for weeks. At TrufaMED in Surfside, our multiplex respiratory panel confirms RSV in approximately 20 minutes and our physicians initiate treatment the same visit.
Respiratory syncytial virus (RSV) was historically considered a pediatric illness, but surveillance over the past decade has established it as a major adult respiratory pathogen. In adults, the presentation is often indistinguishable from a bad cold or a mild flu:
Unlike influenza, RSV rarely produces severe body aches or the sudden fever spikes characteristic of the flu. Symptom onset is gradual, over 2 to 3 days, which sometimes delays patients from seeking care.
Yes. RSV is highly contagious and spreads through respiratory droplets, direct contact with infected secretions, and contact with contaminated surfaces, where the virus can survive for several hours. Key transmission facts:
During the 2025–2026 season, the CDC reports RSV activity peaking between November and February in the southeastern United States, with regional variation.
Severe RSV in adults is concentrated in specific populations:
In these groups, RSV can precipitate asthma and COPD exacerbations, trigger heart failure decompensation, and progress to viral pneumonia requiring hospitalization.
You should be evaluated promptly if you experience:
Severe respiratory distress, bluish lips, or inability to speak full sentences warrants immediate emergency evaluation.
Because RSV, influenza, COVID-19, and other respiratory viruses produce overlapping symptoms, clinical examination alone is insufficient. At TrufaMED, our multiplex respiratory panel tests for RSV, COVID, influenza A, and influenza B from a single nasal swab with results in approximately 20 minutes. Accurate identification matters because:
Learn more about our combined COVID, flu, strep, and RSV testing panel.
Treatment for RSV in adults is primarily supportive:
There is no approved oral antiviral for RSV in ambulatory adults. Ribavirin is reserved for select hospitalized, severely immunocompromised patients. Patients with fatigue and dehydration often benefit from IV hydration therapy while recovering. For patients with concurrent flu-like symptoms, our flu treatment protocol is initiated based on test results.
Healthy adults typically recover fully within 7 to 14 days. Cough can persist for 3 to 4 weeks. Adults with underlying lung disease may experience protracted symptom worsening, and older adults hospitalized for RSV face a documented 1-year mortality approximately double that of age-matched controls.
Two major advances have changed RSV prevention for adults in the past two seasons:
Additional prevention measures include hand hygiene, avoiding close contact with symptomatic individuals, and thorough disinfection of shared surfaces during outbreak periods.
RSV frequently co-circulates with influenza and COVID-19, and adults can be infected with more than one virus concurrently. Any older adult with respiratory symptoms should be tested to identify the specific cause. In pediatric patients, RSV remains a leading cause of bronchiolitis and hospitalization under age 2; our pediatric urgent care team evaluates infants and children seven days a week.
Clinical examination cannot reliably distinguish RSV from other respiratory viruses. A multiplex nasal swab is the only definitive way to confirm the diagnosis.
Most healthy adults are contagious for 3 to 8 days. Immunocompromised adults can shed virus for several weeks.
Yes. Household transmission from symptomatic children to parents and grandparents is one of the most common routes of adult RSV infection.
There is no approved outpatient antiviral for RSV in adults. Treatment is supportive, with bronchodilators and steroids in select cases.
Adults 75 and older are recommended to receive the RSV vaccine. Adults 60 to 74 with risk factors should discuss vaccination with a physician.
Immunity after RSV infection is incomplete and short-lived. Reinfection is common, though subsequent infections are typically milder in immunocompetent adults.
Cough frequently persists for 2 to 4 weeks after the acute illness resolves, particularly in adults with underlying airway disease.
If you are an older adult or have underlying lung or heart disease and develop respiratory symptoms, prompt testing and physician evaluation can prevent avoidable complications. TrufaMED is open Mon-Fri 9 a.m. to 9 p.m., Sat 11 a.m. to 11 p.m., Sun 12 p.m. to 8 p.m., with a physician on site every day. Walk in at 9445 Harding Avenue in Surfside or call (305) 537-6396 to be seen the same day.
Sources: Centers for Disease Control and Prevention (CDC) RSV surveillance and vaccination recommendations, 2025–2026. New England Journal of Medicine reviews on RSV in older adults.